AU2008308761B2 - NLRR-1 antagonists and uses thereof - Google Patents

NLRR-1 antagonists and uses thereof Download PDF

Info

Publication number
AU2008308761B2
AU2008308761B2 AU2008308761A AU2008308761A AU2008308761B2 AU 2008308761 B2 AU2008308761 B2 AU 2008308761B2 AU 2008308761 A AU2008308761 A AU 2008308761A AU 2008308761 A AU2008308761 A AU 2008308761A AU 2008308761 B2 AU2008308761 B2 AU 2008308761B2
Authority
AU
Australia
Prior art keywords
antibody
nlrr
egfr
cancer
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008308761A
Other languages
English (en)
Other versions
AU2008308761A1 (en
Inventor
Meredith Hazen
Jo-Anne S. Hongo
Victoria Smith
Susanna Stinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2008308761A1 publication Critical patent/AU2008308761A1/en
Application granted granted Critical
Publication of AU2008308761B2 publication Critical patent/AU2008308761B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008308761A 2007-10-02 2008-10-01 NLRR-1 antagonists and uses thereof Ceased AU2008308761B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97689207P 2007-10-02 2007-10-02
US60/976,892 2007-10-02
PCT/US2008/078474 WO2009046123A2 (en) 2007-10-02 2008-10-01 Nlrr-1 antagonists and uses thereof

Publications (2)

Publication Number Publication Date
AU2008308761A1 AU2008308761A1 (en) 2009-04-09
AU2008308761B2 true AU2008308761B2 (en) 2014-10-16

Family

ID=40526943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008308761A Ceased AU2008308761B2 (en) 2007-10-02 2008-10-01 NLRR-1 antagonists and uses thereof

Country Status (7)

Country Link
US (1) US8691222B2 (enExample)
EP (1) EP2207805B1 (enExample)
JP (1) JP5695905B2 (enExample)
AU (1) AU2008308761B2 (enExample)
CA (1) CA2699601A1 (enExample)
ES (1) ES2502217T3 (enExample)
WO (1) WO2009046123A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264462B1 (en) * 2008-03-04 2012-11-07 Hisamitsu Pharmaceutical Co., Inc. Screening method for a therapeutic agent for cancer
WO2019222506A1 (en) * 2018-05-16 2019-11-21 Chang Gung Memorial Hospital, Linkou Novel leucine-rich repeat neuronal protein 1 (lrrn1) antibodies and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186866A1 (en) * 2000-09-15 2003-10-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20060099214A1 (en) * 2002-06-11 2006-05-11 Reinhard Ebner Cancer-linked gene as target for chemotherapy
US20060210561A1 (en) * 1999-08-27 2006-09-21 Genentech, Inc. Dosages for treatment with anti-EGFR antibodies
WO2006130135A1 (en) * 2005-05-31 2006-12-07 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2007050798A2 (en) * 2005-10-26 2007-05-03 Five Prime Therapeutics, Inc. Lrrtm1 compositions and methods of their use for the diagnosis and treatment of cancer
US20080311107A1 (en) * 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210561A1 (en) * 1999-08-27 2006-09-21 Genentech, Inc. Dosages for treatment with anti-EGFR antibodies
US20030186866A1 (en) * 2000-09-15 2003-10-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20060099214A1 (en) * 2002-06-11 2006-05-11 Reinhard Ebner Cancer-linked gene as target for chemotherapy
WO2006130135A1 (en) * 2005-05-31 2006-12-07 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2007050798A2 (en) * 2005-10-26 2007-05-03 Five Prime Therapeutics, Inc. Lrrtm1 compositions and methods of their use for the diagnosis and treatment of cancer
US20080311107A1 (en) * 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INOUE, H. et al. PNAS 2007, vol. 104, no. 36, pages 14430-14435 *

Also Published As

Publication number Publication date
US8691222B2 (en) 2014-04-08
EP2207805B1 (en) 2014-07-09
CA2699601A1 (en) 2009-04-09
US20100330082A1 (en) 2010-12-30
WO2009046123A3 (en) 2009-06-25
EP2207805A2 (en) 2010-07-21
AU2008308761A1 (en) 2009-04-09
JP2010540653A (ja) 2010-12-24
WO2009046123A2 (en) 2009-04-09
JP5695905B2 (ja) 2015-04-08
HK1146065A1 (en) 2011-05-13
ES2502217T3 (es) 2014-10-03

Similar Documents

Publication Publication Date Title
US11402382B2 (en) Diagnostic and therapeutic methods for cancer
CN114206930B (zh) 针对抗cd73抗体和变体的方法和组合物
US20090226455A1 (en) Combination therapy with c-met and her antagonists
JP2019521641A (ja) がんを監視及び治療するための方法
TW201819640A (zh) 癌症之治療性及診斷性方法
CN102498129B (zh) 使用bv8拮抗剂或g-csf拮抗剂抑制肿瘤转移
KR20230118704A (ko) Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을치료하는 방법
KR20180008449A (ko) 암에 대한 치료 및 진단 방법
KR20160095186A (ko) Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
CN102216331A (zh) 治疗方法
JP2018529719A (ja) Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
KR20130126576A (ko) 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
AU2008308761B2 (en) NLRR-1 antagonists and uses thereof
JP2010540653A5 (enExample)
HK1146065B (en) Nlrr-1 antagonists and uses thereof
WO2011082187A1 (en) Methods for modulating a pdgf-aa mediated biological response
RU2825390C2 (ru) Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
HK40016679A (en) Therapeutic and diagnostic methods for cancer
AU2017202820A1 (en) Combination therapy with c-met and HER antagonists
HK40018953A (en) Diagnostic and therapeutic methods for cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired